For research use only. Not for therapeutic Use.
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1].
Catalog Number | I040374 |
CAS Number | 2254059-25-9 |
Purity | ≥95% |
Reference | [1]. Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32(3):395-403. |